Twitter was abuzz with a letter from Christopher MacLeod, Canadian Cystic Fibrosis Treatment Society to the President of the Treasury Board, House of Commons & the Auditor General Canada with a request to investigate PMPRB for “targeting & de-legitimizing the Patient Voice”.

Quebec will be moving to a biosimilars only program by April 12, 2022.

COVID-19 is a humanitarian crisis that’s now having a growing impact on Canadian healthcare. Popular opinion seems to be that “the new normal”, whatever that looks like, will not arrive before the second half of 2021.

After several weeks of consultation, the PMPRB has made their decision regarding the definition of Gap Medicines and the compliance timelines for Grandfathered and Gap Medicines.

On February 24, the private members Bill C-213, An Act to enact the Canada Pharmacare Act, was defeated. This Bill, tabled last February 2020 by NDP MP, Peter Julian, had the support of all members of the NDP and Green Party, one Conservative, two Liberal & two independents MPs.

The Government has announced the implementation of the amended Patented Medicines Regulations will be delayed once again until July 1, 2021.

Two new appointments for The Pangaea Group effective January 1, 2021.

Health Canada (HC) has issued an Interim Order (IO) to safeguard Canada’s drug supply from diversion.

The final PMPRB Guidelines have been published along with an "Overview of Final Changes" that differ from the June 2020 draft Guidelines.

On September 16, 2020, the Feds issued an Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 that allows for the Minister of Health to expedite review of COVID-19 drugs in Canada. There are three routes.